Teva Hit With Securities Class Action Over CEO Resignation

Law360, Los Angeles (December 18, 2013, 10:12 PM ET) -- Teva Pharmaceutical Industries Inc. was slapped with a putative class action in New York federal court on Wednesday when a shareholder alleged the company intentionally misled the media and investors about a dispute between the CEO and the board of directors.

Jill Edison alleged the unexpected resignation of CEO Jeremy Levin — just days after the company denied he would resign — caused the company to lose $2.8 billion in market capitalization, according to the suit.

“Plaintiff and the class purchased Teva securities at artificially inflated...
To view the full article, register now.

Dewey Verdict Watch

Follow our exclusive coverage of the trial of the year:

Click here for the latest